Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2018.08.027
Abstract: PURPOSE Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurrent or… read more here.
Keywords: bevacizumab; fallopian tube; ovarian fallopian; persistent ovarian ... See more keywords